SUMOylation-Driven Subtype Heterogeneity and Prognostic Biomarkers in Renal Cell Carcinoma.

Xiaobo Zhang, Zhiming Li, Ruoxin Lin, Suping Yang, Xiaohui Sun, Shicheng Chen

Abstract read

In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaobo ZhangDepartment of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.ORCID 0009-0008-0485-0877

Zhiming LiDepartment of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.

Ruoxin LinDepartment of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.

Suping YangDepartment of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.ORCID 0000-0002-0985-8287

Xiaohui SunDepartment of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.ORCID 0000-0002-9238-4755

Shicheng ChenMedical Laboratory Sciences Program, College of Health and Human Sciences, Northern Illinois University, DeKalb, IL 60115, USA.

Funding

Fujian Provincial Science and Technology Special Program for Key Industrial Chain Services by Special Expert Team 2024N03010414Noncommunicable Chronic Diseases-National Science and Technology Major Project 2026ZB0556800the Quanzhou Major Science and Technology Project 2025QZNZ03Xiamen Key Science and Technology Program (Future Industries Field) 3502Z20254021

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the most common malignancy of the urinary system, characterized by high incidence, mortality, and resistance to therapy. Its molecular heterogeneity presents challenges for effective precision treatment. RCC is highly heterogeneous, yet treatment guidelines rely predominantly on kidney renal clear cell carcinoma (KIRC) studies, neglecting other molecular subtypes, which limits therapy personalization for non-KIRC patients. This study aimed to explore the role of small ubiquitin-like modifier (SUMOylation)-associated genes in the progression and prognosis of RCC and its subtypes. We identified 298 SUMOylation-associated differentially expressed genes (DEGs), including 151 RCC-specific genes after excluding expression changes attributable to RCC subtype-specific variation. Ten core genes (

Indexed as

biomarkersheterogeneityprognosticrenal cell carcinomaSUMOylation

Identifiers

PMID42651750

DOI10.3390/cimb48080751

PMCPMC13511082

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.